Review
Oncology
Cristina Tecchio, Anna Russignan, Mauro Krampera
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefits adult ALL patients, but those with MRD may require interventions with side effects. The significance of MFC in ALL treatment is widely recognized, but there is limited data on MRD monitoring in allo-HSCT settings. This article aims to summarize and discuss the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT, including sensitivity, timing, and relation to other MRD assessment techniques.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Tong-Yoon Kim, Silvia Park, Daehun Kwag, Jong-Hyuk Lee, Joonyeop Lee, Gi-June Min, Sung-Soo Park, Young-Woo Jeon, Seung-Hawn Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee, Hee-Je Kim
Summary: This study evaluated the prognostic value of the European Leukemia Net (ELN) 2017 genetic risk stratification on post-hematopoietic stem-cell transplantation (HSCT) outcomes in patients with acute myeloid leukemia (AML). The study found that the pre-HSCT WT1 level was a better predictor of post-HSCT relapse than the ELN 2017 risk classification, particularly in the intermediate risk group. FLT3-ITD had the greatest impact on post-HSCT outcomes among all the ELN 2017 criteria components.
Article
Immunology
Edyta Heropolitanska-Pliszka, Barbara Piatosa, Anna Szmydki-Baran, Karolina Kuczborska, Karolina Miarka-Walczyk, Agata Pastorczak, Wojciech Mlynarski, Lukasz Sedek, Tomasz Szczepanski, Marek Ussowicz
Summary: This study reports a successful bone marrow transplantation in a carrier of a novel GATA2 pathogenic variant who had previously been treated for B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The study highlights the importance of genetic counseling and family screening prior to selecting related hematopoietic stem cell transplantation (HSCT) donors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David Marks, Hagop M. Kantarjian
Summary: The study demonstrated that InO was more effective than standard intensive chemotherapy for patients with R/R Ph+ ALL, showing higher rates of complete remission and minimal residual disease negativity, as well as improved hematopoietic stem cell transplantation rates. However, there was no significant benefit in overall survival, and the probability of being event-free at 12 months was higher with InO treatment.
Review
Oncology
Na Lin, Zhenghua Liu, Yan Li, Xiaojing Yan, Lei Wang
Summary: SET-CAN/NUP214 fusion is a common event in T-ALL, often associated with resistance to chemotherapy. However, proper treatment selection can lead to good outcomes in patients with this fusion gene. Ex vivo drug sensitivity screening can guide personalized treatment strategies and may help overcome drug resistance.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pediatrics
Hossam Hodeib, Doaa El Amrousy, Amira Youssef, Rasha Khedr, Hassan Al-Asy, Ahmed Shabana, Shimaa Elnemr, Dina Abdelhai
Summary: Overexpression of SALL4 and BMI-1 in children with ALL may indicate a higher risk of relapse.
PEDIATRIC RESEARCH
(2023)
Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Article
Cell & Tissue Engineering
Guangyu Sun, Baolin Tang, Kaidi Song, Yue Wu, Meijuan Tu, Xiang Wan, Wen Yao, Liangquan Geng, Ping Qiang, Xiaoyu Zhu
Summary: This study compared the outcomes of UCBT and MST in the treatment of adult B-ALL patients. The results showed that UCBT had slower hematopoietic recovery but lower incidence of extensive cGVHD. The NRM, relapse, DFS, and GRFS were comparable between MST and UCBT recipients, but UCBT showed better OS for patients with long-term survival.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Oncology
Mixue Xie, Ting Shi, Qi Jiang, Yunlu Jia, De Zhou, Hongyan Tong, Jie Jin, Hong-Hu Zhu
Summary: Chemotherapy plus tyrosine kinase inhibitors (TKIs) leads to a comparable survival benefit as with allo-HSCT for MRD-negative patients in the TKI era.
Article
Oncology
Cuiyan Zhou, Fengmei Zheng, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Nico Gagelmann, Anita Badbaran, Dietrich W. Beelen, Rachel B. Salit, Friedrich Stoelzel, Christina Rautenberg, Heiko Becker, Aleksandar Radujkovic, Victoria Panagiota, Rashit Bogdanov, Maximilian Christopeit, Yong Park, Olivier Nibourel, Thomas Luft, Michael Koldehoff, Maarten Corsten, Michael Heuser, Jurgen Finke, Guido Kobbe, Uwe Platzbecker, Marie Robin, Bart L. Scott, Nicolaus Kroeger
Summary: The study demonstrated that mutation status and clinical presentations impact posttransplant outcomes for newly diagnosed CMML patients, leading to the development of a CMML transplant score predicting survival and nonrelapse mortality. The score showed good performance and accuracy, outperforming existing scores designed for nontransplant settings and enabling significant risk reclassification. The CMML transplant score, incorporating mutation and clinical information, proved to be valuable for personalized counseling in transplant patients.
Article
Medicine, General & Internal
Menglin Fan, Yu Wang, Ren Lin, Tong Lin, Fen Huang, Zhiping Fan, Yajing Xu, Ting Yang, Na Xu, Pengcheng Shi, Danian Nie, Dongjun Lin, Zujun Jiang, Shunqing Wang, Jing Sun, Xiaojun Huang, Qifa Liu, Li Xuan
Summary: This study compared the graft-versus-leukemia (GVL) effect between haploidentical donor (HID) and human leukocyte antigen (HLA)-matched sibling donor (MSD) transplantation for Philadelphia-negative (Ph-) high-risk B-cell acute lymphoblastic leukemia (B-ALL). The results suggested that HID transplantation has a lower incidence of post-MRD+ and a better GVHD-free/relapse-free survival compared to MSD transplantation.
CHINESE MEDICAL JOURNAL
(2022)
Article
Oncology
Yi Fan, Linxiao Liao, Yajun Liu, Zhenzhen Wu, Chong Wang, Zhongxing Jiang, Shujuan Wang, Yanfang Liu
Summary: ASXL1 mutations in AML are associated with adverse prognosis, especially when accompanied by other risk factors like age, high WBC count, specific gene mutations, and absence of fusion genes. Allogenic hematopoietic stem cell transplantation can potentially improve the outcomes of ASXL1+ AML patients with multiple risk factors.
CANCER CELL INTERNATIONAL
(2021)
Article
Hematology
Yoshimitsu Shimomura, Sho Komukai, Tetsuhisa Kitamura, Takayoshi Tachibana, Shuhei Kurosawa, Hidehiro Itonaga, Shokichi Tsukamoto, Noriko Doki, Yuta Katayama, Ayumu Ito, Masashi Sawa, Yasunori Ueda, Hirohisa Nakamae, Yuichiro Nawa, Masatsugu Tanaka, Yasuyuki Arai, Shuichi Ota, Keisuke Kataoka, Tetsuya Nishida, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ken Ishiyama
Summary: This study aimed to identify risk factors for patients with CK-MDS undergoing allogeneic HCT. The results showed that older age, male sex, poor comorbidity index, transfusion requirements, incomplete remission, high number of karyotype abnormalities, and monosomal karyotype were significantly associated with overall survival in CK-MDS patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Hisashi Ishida, Yuki Arakawa, Daiichiro Hasegawa, Ikuya Usami, Yoshiko Hashii, Yasuyuki Arai, Satoshi Nishiwaki, Dai Keino, Keisuke Kato, Maho Sato, Nao Yoshida, Yukiyasu Ozawa, Keiko Okada, Moe Hidaka, Yuki Yuza, Masatsugu Tanaka, Kenichiro Watanabe, Junko Takita, Yoshiyuki Kosaka, Naoto Fujita, Junji Tanaka, Atsushi Sato, Yoshiko Atsuta, Toshihiko Imamura
Summary: In this study, data of Ph+ALL patients receiving HSCT in Japan were retrospectively collected, showing that RIC regimen in HSCT for younger patients had comparable long-term leukemia-free survival rates to the traditional MAC regimen, with RIC being an independent favorable prognostic factor.
ANNALS OF HEMATOLOGY
(2023)
